Discover Pathalys
Opportunity Shouldn’t Depend on Circumstance
At Pathalys Pharma, we believe that innovation should meet patients where they are, not ask more of them. That’s why we are committed to supporting the unique needs of patients through the development of therapeutics that may improve the management of patients living with CKD.
Founded in 2021 with initial funding from Catalys Pacific and DaVita Venture Group, Pathalys was built to be a biopharmaceutical company focused on innovation to meet the needs of patients living with CKD on dialysis.
Company Snapshot
Founded
2021
Headquarters
Raleigh, NC
Lead Candidate
Upacicalcet
Upacicalcet is an investigational product candidate in the United States and has not been approved by the U.S. Food and Drug Administration (FDA).
Clinical Stage
Two Phase 3 Programs
One such unmet need and an initial area of focus for Pathalys is exploring new options for treating secondary hyperparathyroidism (SHPT).
We envision a future where scientific progress in CKD reaches the patients who need it. We believe that every CKD patient on hemodialysis deserves access to innovation and opportunity.
